Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic

Earendil Labs has secured $787 million in financing to expand its AI-based biologics discovery and development platform, with backing from investors including Dimension Capital, DST Global, Sanofi, and a biotech fund formed by Hillhouse and Pfizer. The funding is intended to support pipeline expansion, team growth, and advancement of multiple antibody programs toward clinical stages.